Investigation of clinicopathological features of vulvar cancer in 1068 patients: A Japanese Gynecologic Oncology Group (JGOG) nationwide survey study

Nishio, Yukihiro; Murotani, Kenta; Nakao, Sari; Takenaka, Motoki; Suzuki, Shiro; Aoki, Yoichi; Todo, Yukiharu; Hosaka, Masayoshi; Katabuchi, Hidetaka; Nishi, Hirotaka; Takekuma, Munetaka; Mikami, Mikio; Enomoto, Takayuki

doi:10.1016/j.ygyno.2020.08.019

Cited by 6 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The common histological types of VC include SCC, vulvar intraepithelial neoplasms, malignant melanoma, adenocarcinomas and basal cell carcinomas. SCC was the most commonly diagnosed form of VC in this study (87%), which is consistent with previous reports [20,21], and the type of malignant melanoma was associated with a poorer OS for patients with VC. A previous article showed that melanoma was the second most common cancer affecting the vulva, and staging was based on tumor, node, and metastatic spread, [3] -45-older age, higher tumor grade and larger tumor size had a decreased OS, and malignant melanoma and tumors with diameters >4 cm had the lowest survival rates.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Establishment and validation of a nomogram for predicting overall survival in patients with vulvar carcinoma based on the SEER database

2021

FMSR

View full text Add to dashboard Cite

Background: Vulvar carcinoma (VC) is a rare female gynecological malignancy, and optimizing prognostic factors for VC requires large-scale research containing various clinical indicators of patients. Our study attempted to develop and validate a detailed survival nomogram for predicting the overall survival (OS) probability in patients diagnosed with VC. Methods: Patients diagnosed with VC between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox regression analyses were performed followed by the construction of the nomogram for OS. The performance of this model was evaluated using the concordance index (C-index), area under the time-dependent receiver operating characteristics curve (AUC), net reclassification improvement (NRI), integrated discrimination improvement (IDI), calibration plots and decision curve analysis (DCA). In addition, the C-index, AUC and DCA of the model and the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system were compared. Results: A total of 6275 patients were randomly assigned to the training cohort (n=4392) and the validation cohort (n=1883). Multivariate analysis identified independent prognostic factors (p<0.05) for OS, including histological type, age, surgery, T stage, N stage, M stage, grade, summary stage, chemotherapy, race, marital status and size. Finally, a nomogram was constructed to predict the 3-, 5-, and 8-year OS probabilities for patients with VC, and the C-index, NRI, IDI and calibration plotting all showed that the model has good discrimination. Additionally, the nomogram also showed better clinical validity of the DCA and AUC compared to that of the FIGO system. Conclusions: We developed and validated a nomogram for individual OS prediction in patients with VC. While further validation is required, this nomogram may be a useful comprehensive prognostic tool to give patients a better idea of prognosis during counseling.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Typically, patients with VC are primarily treated with surgery, depending on the pathology and extent of the disease, with the option of adjuvant radiation or chemotherapy [23]. Although radical vulvectomy is effective, it was found to be associated with serious adverse effects, including wound complications and lymphedema [20].…”

Section: Discussionmentioning

confidence: 99%

Establishment and validation of a nomogram for predicting overall survival in patients with vulvar carcinoma based on the SEER database

2021

FMSR

View full text Add to dashboard Cite

show abstract

“…Considering that the median age of the population was 76 years, and the combined Stage III and IV population was over 70%, RT/CCRT for VC would be an effective treatment option. In accordance with the Japanese Nationwide Study, the 5-year OS rates of patients with stage I, II, III, and IV VC who underwent surgical treatment were 85.6%, 75.1%, 48.8%, and 40.0%, respectively [ 9 ]. These results suggest that, if tumors are medically resectable, surgical procedures should be recommended first.…”

Section: Discussionmentioning

confidence: 92%

“…This was a sub-analysis of a multicenter, retrospective, observational study. The protocol for this study was approved by the ethics committee of each participating institution (108 Japanese Gynecologic Oncology Group [JGOG] affiliated institutions) [ 9 ]. The study was registered with the University Hospital Medical Information Network (UMIN) (protocol number: UMIN000017080).…”

Section: Methodsmentioning

confidence: 99%

“…The inclusion criteria for the original study were as follows: histologically proven and treated VC, including patients whose initial therapy was of palliative intent, and cases of primary vulvar cancer with all histologic types, with the exception of malignant melanoma. The details are summarized in our previous study [ 9 ]. The data were collected from 108 JGOG-affiliated institutions between August 2014 and March 2016, and included stage, histology, treatment intensity (curative or palliative), treatment modality (surgery, RT, chemotherapy), RT dose, and survival periods.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Significance of definitive concurrent chemoradiotherapy for vulvar cancer: a Japanese Gynecologic Oncology Group nationwide survey study

Okonogi,

Tsuchida,

Ando

et al. 2024

Jpn J Radiol

Self Cite

View full text Add to dashboard Cite

Objective This study aimed to show the results of radical radiation therapy (RT) and concurrent chemoradiotherapy (CCRT) for vulvar cancer (VC) based on data from a Japanese nationwide survey. Materials and methods We collected data from 108 institutions on cases of VC diagnosed between January 2001 and December 2010. Patients with histologically proven squamous cell carcinoma and adenocarcinoma with curative intent were selected, and 172 patients with VC were included in this study. The collected data were analyzed for overall survival (OS) using the Kaplan–Meier method. Univariate and multivariate analyses were performed to examine the prognostic factors for patients with VC. Results The median follow-up period was 16.8 (range; 3.2–154.8) months. Fifty-five patients received CCRT, and 117 patients received RT alone. The 2-year OS rates (95% confidence interval [CI]) for stages I, II, III, and IV were 77.9% (55.8–100.0), 71.9% (53.8–89.9), 55.4% (42.5–68.3), and 41.5% (27.3–55.7) respectively. Univariate analyses showed that the FIGO stage (p = 0.001), tumor diameter (p = 0.005), and lymph node (LN) status (p = 0.001) were associated with OS. The concurrent use of chemotherapy resulted in a significantly longer OS in Stage III (p = 0.013). Multivariate analysis showed that the hazard ratios (95% CI) for tumor diameter, positivity for LN metastasis, and RT alone (no concurrent chemotherapy) were 1.502 (1.116–2.021), 1.801 (1.287–2.521), and 1.936 (1.187–3.159), respectively. Conclusions Our analysis revealed that CCRT should be recommended, especially for Stage III VC patients. Further studies are warranted to determine who benefits from CCRT, considering primary tumor size and LN status. The study was registered at the University Hospital Medical Information Network (protocol number: UMIN000017080) on April 8th, 2015.

show abstract

Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: A retrospective cohort study based on the SEER database

Meng,

Guo,

Feng

et al. 2024

Cancer Pathogenesis and Therapy

View full text Add to dashboard Cite

Investigation of clinicopathological features of vulvar cancer in 1068 patients: A Japanese Gynecologic Oncology Group (JGOG) nationwide survey study

Cited by 6 publications

References 17 publications

Establishment and validation of a nomogram for predicting overall survival in patients with vulvar carcinoma based on the SEER database

Establishment and validation of a nomogram for predicting overall survival in patients with vulvar carcinoma based on the SEER database

Significance of definitive concurrent chemoradiotherapy for vulvar cancer: a Japanese Gynecologic Oncology Group nationwide survey study

Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: A retrospective cohort study based on the SEER database

Contact Info

Product

Resources

About